Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-05-15 4:04 pm Purchase | 2025-03-31 | 13G | Lyell Immunopharma, Inc. LYEL | Foresite Capital Fund IV, L.P. | 1,358,095 9.200% | 384,150 (+39.44%) | Filing History |
| 2025-02-14 4:55 pm Purchase | 2024-12-31 | 13G | Lyell Immunopharma, Inc. LYEL | ARCH Venture Fund IX, L.P. | 1,829,886 13.100% | 6,000 (+0.33%) | Filing History |
| 2025-02-14 2:20 pm Purchase | 2024-12-31 | 13G | Lyell Immunopharma, Inc. LYEL | Foresite Capital Fund IV, L.P. | 973,945 6.700% | 289,752 (+42.35%) | Filing History |
| 2025-02-05 1:23 pm Sale | 2024-12-31 | 13G | Lyell Immunopharma, Inc. LYEL | BlackRock Inc. BLK | 663,293 4.500% | -51,818 (-7.25%) | Filing History |
| 2024-11-12 4:04 pm Unchanged | 2024-09-30 | 13G | Lyell Immunopharma, Inc. LYEL | The Vanguard Group | 503,574 3.930% | 0 (Unchanged) | Filing History |
| 2024-11-04 1:30 pm Sale | 2024-09-30 | 13G | Lyell Immunopharma, Inc. LYEL | The Vanguard Group | 503,574 3.930% | -176,627 (-25.97%) | Filing History |
| 2024-10-31 6:00 pm Purchase | 2024-10-25 | 13G | Lyell Immunopharma, Inc. LYEL | Foresite Capital Fund IV, L.P. | 684,193 5.300% | 184,193 (+36.84%) | Filing History |
| 2024-02-14 3:18 pm Purchase | 2023-12-31 | 13G | Lyell Immunopharma, Inc. LYEL | ARCH Venture Fund IX, L.P. | 1,823,886 14.500% | 3,250 (+0.18%) | Filing History |
| 2024-02-13 5:08 pm Purchase | 2023-12-29 | 13G | Lyell Immunopharma, Inc. LYEL | The Vanguard Group | 680,201 5.400% | 50,640 (+8.04%) | Filing History |
| 2024-01-29 5:25 pm Purchase | 2023-12-31 | 13G | Lyell Immunopharma, Inc. LYEL | BlackRock Inc. BLK | 715,111 5.700% | 715,111 (New Position) | Filing History |
| 2023-02-13 5:02 pm Sale | 2022-12-31 | 13G | Lyell Immunopharma, Inc. LYEL | Foresite Capital Fund IV, L.P. | 500,000 4.000% | -164,109 (-24.71%) | Filing History |
| 2023-02-09 11:25 am Purchase | 2022-12-30 | 13G | Lyell Immunopharma, Inc. LYEL | The Vanguard Group | 629,562 5.050% | 629,562 (New Position) | Filing History |
| 2022-02-14 4:17 pm Purchase | 2021-12-31 | 13G | Lyell Immunopharma, Inc. LYEL | MWG Management Ltd. | 1,008,117 8.380% | 1,008,117 (New Position) | Filing History |
| 2022-02-14 4:10 pm Purchase | 2021-12-31 | 13G | Lyell Immunopharma, Inc. LYEL | NEWTON (PTC) Ltd | 754,698 6.280% | 754,698 (New Position) | Filing History |
| 2022-02-14 12:04 pm Purchase | 2021-12-31 | 13G | Lyell Immunopharma, Inc. LYEL | ARCH Venture Fund IX, L.P. | 1,820,636 15.100% | 1,820,636 (New Position) | Filing History |
| 2022-02-11 3:10 pm Purchase | 2021-12-31 | 13G | Lyell Immunopharma, Inc. LYEL | Foresite Capital Fund IV, L.P. | 664,109 5.500% | 664,109 (New Position) | Filing History |
| 2022-02-10 4:51 pm Purchase | 2021-12-31 | 13G | Lyell Immunopharma, Inc. LYEL | GSK PLC | 1,512,659 12.600% | 1,512,659 (New Position) | Filing History |